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Abstract. Small molecules containing cyclopropane–heteroatom linkages are commonly needed in 
medicinal chemistry campaigns, yet are problematic to prepare using existing methods. To address this 
issue, a scalable Chan–Lam cyclopropylation reaction using potassium cyclopropyl trifluoroborate has 
been developed. With phenol nucleophiles, the reaction effects O-cyclopropylation, whereas with 2-
pyridones, 2-hydroxybenzimidazoles, and 2-aminopyridines the reaction brings about N-
cyclopropylation. The transformation is catalyzed by Cu(OAc)2 and 1,10-phenanthroline and employs 1 
atm O2 as the terminal oxidant. This method is operationally convenient to perform and provides a 
simple, strategic disconnection toward the synthesis of cyclopropyl aryl ethers and cyclopropyl amine 
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derivatives bearing an array of functional groups. 
Introduction. Cyclopropyl groups are prevalent in drug molecules and bioactive compounds,1 with 8 of 
the top 200 best-selling therapeutics from last year containing a cyclopropyl moiety.2 As such, methods 
for introducing these substituents are of significant interest in both academia and the pharmaceutical 
industry. The goal of the present study was to expand the synthetic toolkit for appending cyclopropyl 
groups to phenols and aza-heterocycles. 
Medicinal Chemistry Considerations. The rationale for incorporating cyclopropyl substituents in 
the context of medicinal chemistry merits a brief introduction. Sound decision-making in drug discovery 
campaigns is often guided by disciplined optimization of lipophilic efficiency (LipE), a metric that is 
used to capture the efficiency of a compound’s potency as a function of its lipophilicity.3 Increasing the 
lipophilicity of a compound or series in the absence of other changes can often result in higher 
metabolic clearance and thus higher dosing requirements to achieve sufficient efficacy. Therefore, from 
a practical standpoint, judicious use of lipophilic groups is advised and the metabolic consequences of 
their incorporation should be considered in parallel to any observed potency gain. 
To interrogate the metabolic stability of the cyclopropyl functionality within the context of drug-like 
molecules, we performed a pairwise analysis of matched molecular pairs (MMPs) for a series of 
cyclopropyl-to-alkyl group transforms using the Pfizer database and tools developed by our 
computational ADME group.5 For this analysis, we focused on mining MMPs for transforms of interest 
that contained clearance endpoints from Pfizer’s high-throughput human liver microsome (HLM) assay. 
Figure 1 summarizes the transforms that were examined and the corresponding statistics; for each 
transformation, the percentages of cases that fall into each of three categories (decrease, no change, or 
increase) are represented by the color-coded pie chart, and the numerical values represent the 
corresponding mean change with the associated confidence interval. The data show that, on average, 
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cyclopropyl ring-opening transforms (i-Pr, 2a and n-Pr, 2b) along with ring expansion transforms 
(cyclobutyl, 2c and cyclopentyl, 2d) result in an increase in HLM clearance.5 It is important to point out 
the intrinsic variability in the HLM assay, as illustrated by the relatively wide confidence intervals 
observed. Nevertheless, general trends are useful to analyze, and these increases in microsomal 
clearance can be rationalized as a result of increasing lipophilicity across the aforementioned 
transformations.6 To demonstrate this point, we evaluated the transform of cyclopropyl 1 (clogP ~1.6) to 
ethyl 2e (clogP ~1.7), having approximately equal lipophilic contributions, and found no meaningful 
change in clearance for 82% of the 1752 MMPs with HLM data. Therefore, it is not surprising that 
methyl-bearing MMPs 2f (clogP Me~1.1) show a 30% increase in microsomal stability, and thus 
represent the only transform examined with a clear metabolic advantage to cyclopropyl substitution. 
Improving metabolic stability in a series is a common medicinal chemistry objective in order to improve 
pharmacokinetic properties.7 In light of this analysis, new methodologies to introduce the cyclopropyl 
motif are warranted and believed to be of broad interest due to the privileged nature of this functionality. 
 
Figure 1. Transformations examined to probe trends in microsomal stability. For each transform, the 
number of total matched molecular pairs (MMPs) with human liver microsome (HLM) unbound 
intrinsic clearance (CLint,u) is provided below the individual pie chart, along with the total number of 
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+12.8 ± 2.7 mL/min/kg
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into each of three categories (decrease, no change, or increase) are represented by the color-coded pie 
chart, where increase and decrease are defined by a ±20% change. The numerical value immediately 
beneath each pie chart represents the mean change in HLM Clint corresponding with that transform.  
 
Figure 2. Representative bioactive compounds bearing cyclopropylaryl ethers.9 
 
While methodology to access cyclopropyl amines has been vigorously pursued in recent years,8 
cyclopropyl ethers have received less attention. Nevertheless, small molecules containing cyclopropyl 
aryl ethers have a range of biological activities across several different medical indications (Figure 2).9 
Despite their utility, current methods for their synthesis remain limited and sometimes incompatible 
with structurally complex, heteroatom-rich substrates. This gap in synthetic methodology motivated the 
present study. 
Results and Discussion. In terms of synthetic strategy, the most prudent retrosynthetic 
disconnection of a cyclopropyl aryl ether is of the O–c-Pr bond to give the corresponding phenol and a 
cyclopropyl source. The alternative disconnection of the Ar–O bond is complicated by the fact that 
cyclopropanol readily rearranges to form propanal.10 Indeed, this retrosynthetic logic underlies all 
existing methods (Scheme 1).11–13 In one approach, a multi-step sequence consisting of O-alkylation 
with a 1,2-dihaloethane electrophile, base-mediated E2 elimination, and Simmons–Smith 
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cyclopropanation11 is used. While this route provides access to the desired compounds, it requires at 
least three steps, uses reagents with poor functional group compatibility, and can be low-yielding 
(Scheme 1a).11b A second approach is the reaction between a cyclopropyl halide electrophile and a 
phenoxide nucleophile in a Williamson ether synthesis (Scheme 1b).12 Unfortunately, cyclopropyl 
halides are poor electrophiles in SN2 reactions and can undergo competitive E2 elimination. Thus, high 
temperatures (typically ≥150 °C) are required to enable addition of the aryloxide into the corresponding 
in situ formed cyclopropene. Under these forcing conditions, functional group compatibility can be 
limited and formation of undesired allyl-containing byproducts is sometimes observed. A third strategy 
was reported in 1999 by Hollingworth and coworkers. This method exploits a sulfur-stabilized 
carbocation in a modified SN1 reaction to form the key O–C(cyclopropyl) bond. Subsequent 
oxidation/reduction then excises the sulfide (Scheme 1c).13 While inventive, this route nonetheless 
suffers from limited phenol substrate scope due to the difficulty of the SN1 step with electron-poor 




Scheme 1. Comparisons of different methods for O-cyclopropylation of phenols.11–13 
The limitations of these existing methods prompted us to consider an alternative, whereby a 
phenol could react with a nucleophilic cyclopropyl source in an oxidative coupling reaction. We 
envisioned that a reaction of this type would avoid the aforementioned complications with cyclopropyl 
A. Haloalkylation/E2 elimination/Simmons–Smith
OH  1.  CH2BrCH2Cl, K2CO3
2. t-BuOK
3. CH2I2, ZnEt2
B.  Williamson ether synthesis
OH O
C. Modified SN1 reaction
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halide electrophiles and would not require any additional concession steps. Herein, we describe the 
realization of this idea and report a new method for generating cyclopropyl aryl ethers using Chan–
Lam-type coupling.14 While the initial focus was on phenols, it was later found that this protocol is also 
efficient for N-cyclopropylation with select aza-heterocycles (vide infra).  
Reaction Optimization. At the outset, we took inspiration from recent reports on Chan–Lam 
N-cyclopropylation for the preparation of cyclopropylamine derivatives.8 Of particular importance for 
our investigation, Mudryk and coworkers reported that N-cyclopropyl 4-nitrobenzenesulfonamide 
(pKa(DMSO) 13.9 for NsNH2)15 underwent Chan–Lam coupling with cyclopropyl boronic acid,8d 
lending credence to the notion that phenols (pKa(DMSO) = 10–19) would be of an appropriate acidity 
and would be sufficiently nucleophilic to be competent reaction partners. This approach was further 
motivated by other recent reports on Chan–Lam O- and N-alkylation using alkyl boronates/boronic 
acids.16–18 To the best of our knowledge, there is only one example in which a phenol has been reported 
to react with a cyclopropylboronic acid in the presence of a copper promoter. In a 2010 patent, Cacatian 
and coworkers report a single reaction proceeding in 13% yield using 1 equivalent of Cu(OAc)2 and 2 
equivalents of bipyridine.19 
 




phen = 1,10-phenanthroline, bipy = 2,2’-bipyridine. a Reaction conditions (unless otherwise 
specified): 3a (0.3 mmol), 4 (0.9 mmol), solvent, 1 atm O2 (balloon), 12 h, 70 °C. b 1H NMR yield using 
dibromomethane as internal standard. c Reaction run under air instead of an O2 balloon. 
 
Based on these earlier precedents, we began our reaction optimization efforts using cyclopropyl 
boronic acid as the coupling partner in the presence of catalytic quantities of copper(II) salts. While we 
did observe product formation under these conditions, we soon turned to the more stable potassium 
trifluoroborate salt due to inconsistent results with cyclopropyl boronic acid, which we believe stems 
from its decomposition during reaction setup (evidenced by a visible yellowing of the typically white 
solid).20 To our delight, the use of potassium cyclopropyl trifluoroborate nearly doubled the yield and 
improved reproducibility. Using 1 atm O2 as the terminal oxidant, we were pleased to find that the 
reaction led to consistent product formation with only 10% Cu(OAc)2 (Table 1). Interestingly, the use of 
bidentate ligands dramatically improved the efficiency of the reaction, with 1,10-phenanthroline 
ultimately providing the highest yield (entries 10 and 12). The optimal solvent mixture was found to be 
3:1 toluene:H2O. We believe that water is necessary for solubilizing the reaction components and 
promoting transmetalation by facilitating formation of the mixed boronate species via hydrolysis.21 
Various bases were screened (entries 5–6), and K2CO3 proved to be optimal. It was found that the 
BF3K
solvent, 70 ˚C, 12 h
1 atm O2 (balloon)
+
OH O













20% pyridine --- DCE/H2O (2:1) 24
20% pyridine --- toluene/H2O (2:1) 35
20% pyridine toluene/H2O (2:1) 47
10% bipy toluene/H2O (2:1)
20% pyridine toluene/H2O (2:1) 41
20% pyridine --- MeCN/H2O (2:1) 21
--- 20% pyridine --- 0
20% pyridine toluene/H2O (1:1) 43
20% pyridine toluene/H2O (3:1) 36












































reaction vessel must be purged with an O2 balloon and left under an atmosphere of O2 for the duration of 
the reaction to achieve optimal yields.22 With 95% N2/ 5% O2 gas mixtures, the reaction only delivered 
trace product (<5%) after 3 hours. Other oxidants, such as ditertbutylperoxide, did not give the desired 
product in appreciable yield (<5%). Simply running the reaction open to air or purging the reaction 
vessel with O2 and sealing it resulted in reduced yields (entry 11). The reaction proceeded with good to 
high yields over a large variety of copper(II) species. Notably, copper(II) formate (Cu(HCO2)2), a 
copper(II) species that is seldom used in Chan–Lam coupling was found to be nearly as effective as the 
optimal catalyst, Cu(OAc)2. Copper(I) salts also provided the desired product in moderate yield (entries 
15 and 16). Ultimately, Cu(OAc)2 was used for subsequent studies because of its efficiency in the 
reaction and its widespread availability. 23 
Substrate Scope. Having optimized the reaction conditions, we next examined the scope of 
phenol nucleophiles (Table 2). Phenols with diverse functional groups, differing electronic properties, 
and varied substitution patterns were tested. In most cases, the desired product was obtained in moderate 
to high yield (5a–r).  Phenols containing one or more electron-donating substituents at the ortho-, meta-, 
or para- position on the aromatic ring were generally high-yielding, with the reaction tolerating ethers, 
thioethers, and alkyl groups (5a–5g). Substitution at the ortho-position led to diminished yields, likely 
due to steric hindrance (5d). Furthermore, the reaction proceeds smoothly in the presence of halide 
substituents (5h–k), which presents the opportunity to diversify the products via subsequent cross-
coupling. The introduction of strong electron-withdrawing groups at either the meta- or para-positions 
led to lower yields, requiring higher catalyst loading (5l–o). Moreover, in these cases, competitive 
formation of the undesired O-allylated byproduct was observed. We postulate that this is due to the 
attenuated nucleophilicity of the corresponding electron-poor phenoxides, which could potentially 
reduce the affinity of the substrate for the Cu(II) center and/or raise the activation energy for the C–O 
reductive elimination step. Although the yields are generally lower for electron-poor phenols, it is 
important to note that the reaction is nevertheless compatible with a wide variety of functional groups 
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that one might encounter in medicinal chemistry, such as esters, nitriles, halogens, and nitro groups, 
providing preparatively useful quantities of the product in all of these cases. Notably, methyl ester does 
not hydrolyze under the reaction conditions and gives the desired cyclopropylated product (5l). We were 
pleased to observe that the reaction proceeded to a modest extent in the presence of various heterocycles 
(5p–r), including those that could potentially bind to copper.  
 
Table 2. Substrate scope of phenol O-cyclopropylation.a  
 
a All reactions were run on 0.3 mmol scale unless noted otherwise. b Percentages correspond to 
isolated yields. c 25 mol% Cu(OAc)2, 12.5 mol% phen. d 25 mol% Cu(OAc)2, 25 mol% phen. 
 
We also established that the reaction could be performed on larger scale. In particular, 6 mmol of 
our standard substrate, p-phenyl phenol (3a), yielded 81% (>1 gram) of the desired cyclopropylated 
product 5a.  
These reaction conditions are not generally effective in promoting N-cyclopropylation of 

































































conditions. Nevertheless, extensive screening of potential reaction partners revealed three classes of aza-
heterocycles, 2-pyridones,24 2-aminopyridines,25 and 2-hydroxybenzimidazoles, are reactive substrates 
using this method (Table 3). Interestingly, subjecting simple 2-hydroxybenzimidazole to the reaction 
conditions resulted in bis-N,N’-cyclopropylation in high yield (8a). Although 2-hydroxpyridine itself 
reacted smoothly to form product 9b, other derivatives were cyclopropylated in lower yields (9a–g). 
2-Aminopyridine derivatives were also reactive; in this case, the exo-cyclic nitrogen proved to be the 
more reactive position (10a–c). In compound 10c the amide is preferentially functionalized over the free 
phenol, likely due to the two electron-withdrawing carbonyl substituents, which are expected to 
attenuate reactivity. 
Table 3. Substrate scope of azaheterocycle N-cyclopropylation.a 
 
a All reactions were run on a 0.3–0.6 mmol scale. Percentages correspond to isolated yields. 
b 13% of the mono-cyclopropylated product (8a’) was also isolated. c With 10% Cu(OAc)2 and 10% 
phen under otherwise identical conditions: 49% 8a (bis), 15% 8a’ (mono). The connectivity of 8a’ was 
confirmed by single-crystal X-ray diffraction (see SI). d 25 mol% Cu(OAc)2, 25 mol% phen. 
 
 
Conclusion. In summary, we have developed a Chan–Lam protocol for O-cyclopropylation of 
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precatalyst with 1 atm O2 as the terminal oxidant and allows for a range of structurally and functionally 
diverse nucleophiles to be smoothly coupled with potassium cyclopropyl trifluoroborates in good to 
high yields. A broad range of functional groups, including halides, ethers, esters, heterocycles, and nitro 
groups were tolerated. Compared to existing synthetic methods, this approach has several advantages. It 
is operationally convenient to perform, uses commercially available reagents, employs an inexpensive 
copper(II) catalyst, has high levels of functional group tolerance, and gives minimal byproduct 
formation in most cases. We envision that this reaction will find immediate use in medicinal chemistry 
laboratories as a tool for late-stage installation of cyclopropyl groups. Additionally, in the long term, it 
could potentially be adapted for use on larger scale in early- or late-stage development. 
 
Experimental Section. 
General Information. Unless otherwise noted, all materials were used as received from commercial 
sources without further purification. Consistently high yields were obtained with potassium 
cyclopropyltrifluoroborate purchased from Boron Molecular. Batches from other suppliers sometimes 
afforded lower yields; we therefore recommend calibrating the reaction using the 4-phenylphenol 
substrate and purifying the trifluoroborate salt via soxhlet extraction if yields are lower than expected. 
1H and 13C spectra were recorded on Bruker DRX-500 and AV-600. Spectra were internally referenced 
to SiMe4 or solvent signals. The following abbreviations (or combinations thereof) were used to explain 
multiplicities: b = broad, s = singlet, d = doublet, t = triplet, q = quartet, and m = multiplet. High-
resolution mass spectra (HRMS) were recorded on an Agilent ESI-TOF (LC/MSD TOF); compounds 
that could not be ionized under these conditions were measured on an Agilent 5973 Inert GC-MS mass 
spectrometer. Compounds with no mass spec data reported in this manuscript could not be ionized on 
either of these machines. Of the compounds that could not be ionized, five representative examples were 
further analyzed by elemental analysis. Melting points were measured on a MEL-TEMP II (Laboratory 
Devices, USA) apparatus and are uncorrected 
 
General Procedure for O- and N-Cyclopropylation of Phenols and Azaheterocycles: To a 5-mL 
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scintillation vial equipped with a Teflon-coated magnetic stir bar were added the phenol substrate (0.3 
mmol), cyclopropyl potassium trifluoroborate (133.2 mg, 0.9 mmol), Cu(OAc)2, 1,10-phenanthroline, 
and K2CO3 (83.0 mg, 0.6 mmol). The vial was charged with toluene (0.5 mL) and water (0.15 mL) and 
sealed with a septum cap. Caution! Because the reaction involves heating an organic solvent under O2, 
a blast shield should be used at all times, particularly in large-scale experiments. After the indicated 
reaction time, the reaction vessel should be allowed to cool to room temperature behind the blast shield 
prior to workup. The septum was pierced with a 21G needle connected to an O2 balloon. The septum 
cap was partially unscrewed to purge the vial for 5 seconds and then resealed by tightening the cap. The 
reaction was stirred under O2 (balloon) at 70 °C for 12 h, after which it was quenched with sat. NH4Cl 
(aq.) and extracted with EtOAc. The combined organics were dried over MgSO4, filtered and 
concentrated in vacuo. 1H NMR yields were determined by integration of the cyclopropyl product peak 
relative to 1.0 equiv dibromomethane as internal standard. Crude products were then purified by silica 
flash column chromatography. The optimal catalyst/ligand loading was found to vary depending on the 
substrate employed: 
• General Procedure A (typical phenol substrates):  
Cu(OAc)2 (5.4 mg, 10 mol %), 1,10-phenanthroline (5.4 mg, 10 mol %)  
• General Procedure B (electron-poor phenols and azaheterocycles):  
Cu(OAc)2 (13.6 mg, 25 mol%), 1,10-phenanthroline (6.8 mg, 12.5 mol%) 
• General Procedure C (Pfizer examples, more valuable substrates) 
Cu(OAc)2 (13.6 mg, 25 mol%), 1,10-phenanthroline (13.5 mg, 25 mol%) 
 
Characterization of New Compounds: 
Data for O-cyclopropyl aryl ether products 5a–5r and N-cyclopropylated azaheretocycle products 8a– 
8d, 9a–9g, 10a–10c as well as starting material S4 are included below. Original NMR spectra can be 





4-Cyclopropoxy-1,1'-biphenyl (5a): The title compound was prepared from 4-phenylphenol (54 mg, 
0.3 mmol) according to General Procedure A. Purification by silica gel chromatography with 10:1 
hexanes:EtOAc as the eluent gave the product as a white solid (52.9 mg, 84% yield). mp = 109–110 ºC; 
1H NMR (500 MHz, CDCl3) δ 7.65–7.49 (m, 4H), 7.42 (t, J = 7.7 Hz, 2H), 7.33–7.28 (m, 1H), 7.12 (d, 
J = 8.7 Hz, 1H), 3.81–3.75 (m, 1H), 0.81 (d, J = 4.5 Hz, 4H); 13C NMR (150 MHz, CDCl3) δ 128.9, 
128.2, 126.9, 115.4, 51.0, 6.4. EA calc’d for C15H14O: C, 85.68%; H, 6.71%, found: C, 85.31%; H, 
6.81%. 
 
1-(tert-Butyl)-4-cyclopropoxybenzene (5b): The title compound was prepared from 4-(tert-
butyl)phenol (45 mg, 0.3 mmol) according to general procedure A. Purification by silica gel 
chromatography with 10:1 hexanes:EtOAc as the eluent gave the product as a yellow oil (41.0 mg, 72% 
yield). 1H NMR (500 MHz, CDCl3) δ 7.30 (d, J = 8.8 Hz, 2H), 6.98 (d, J = 8.8 Hz, 2H), 3.71 (dq, J = 
5.9, 4.4 Hz, 1H), 1.30 (s, 9H), 0.76 (d, J = 4.1 Hz, 4H); 13C NMR (150 MHz, CDCl3) δ 157.0, 144.0, 
126.5, 114.8, 100.0, 51.1, 34.5, 32.0, 6.6; GC/MS (EI) m/z calcd for C13H18O [M]+ 190.1358, found 190. 
 
1,3-Di-tert-butyl-5-cyclopropoxybenzene (5c): The title compound was prepared from 3,5-di-tert-
butylphenol (61.8 mg, 0.3 mmol) according to General Procedure A. Purification by silica gel 
chromatography with 10:1 hexanes:EtOAc as the eluent gave the product as a colorless oil (30.9 mg, 
42% yield). 1H NMR (500 MHz, CDCl3) δ 7.04 (t, J = 1.7 Hz, 1H), 6.92 (d, J = 1.6 Hz, 2H), 3.79–3.60 
(m, 1H), 1.32 (s, 18H), 0.77 (d, J = 6.4, 3.6, 1.6 Hz, 4H); 13C NMR (150 MHz, CDCl3) δ 158.6, 152.2, 
115.3, 109.4, 50.6, 35.1, 31.6, 6.3; GC/MS (EI) m/z calcd for C17H26O [M]+ 246.1984, found 246. 
 
2-Cyclopropoxy-1,4-dimethylbenzene (5d): The title compound was prepared from 2,5-
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dimethylphenol (36.6 mg, 0.3 mmol) according to General Procedure A. Purification by silica gel 
chromatography with 10:1 hexanes:EtOAc as the eluent gave the product as a yellow oil (22.3 mg, 46% 
yield). 1H NMR (500 MHz, CDCl3) δ 7.03–6.93 (m, 2H), 6.69 (dt, J = 7.4, 1.2 Hz, 1H), 3.79–3.64 (m, 
1H), 2.35 (s, 3H), 2.13 (s, 3H), 0.88–0.64 (m, 4H); 13C NMR (150 MHz, CDCl3) δ 157.3, 136.8, 130.7, 
123.7, 121.4, 113.4, 50.9, 21.9, 16.1, 6.7. 
 
(4-Cyclopropoxyphenyl)(methyl)sulfane (5e): The title compound was prepared from 4-
(methylthio)phenol (42 mg, 0.3 mmol) according to General Procedure A. Purification by silica gel 
chromatography with 10:1 hexanes:EtOAc as the eluent gave the product as a yellow solid (32.4 mg, 
60% yield). mp = 52–55 ºC; 1H NMR (500 MHz, CDCl3) δ 7.28 (d, J = 8.8 Hz, 2H), 6.99 (d, J = 8.8 
Hz, 2H), 3.75–3.67 (m, 1H), 2.44 (s, 3H), 0.76 (d, J = 3.0 Hz, 4H); 13C NMR (150 MHz, CDCl3) δ 
157.9, 130.4, 129.5, 116.1, 51.3, 18.4, 6.6. EA calc’d for C10H12OS: C, 66.63%; H, 6.71%, found: C, 
66.98%; H, 7.11%. 
 
 
1-(Benzyloxy)-4-cyclopropoxybenzene (5f): The title compound was prepared from 4-
(benzyloxy)phenol (60 mg, 0.3 mmol) according to General Procedure A. Purification by silica gel 
chromatography with 10:1 hexanes:EtOAc as the eluent gave the product as an off-white solid (45.0 mg, 
63% yield). mp = 77–79 ºC; 1H NMR (500 MHz, CDCl3) δ 7.41 (d, J = 7.6 Hz, 2H), 7.36 (t, J = 7.5 Hz, 
2H), 7.31 (d, J = 7.2 Hz, 1H), 6.96 (d, J = 9.2 Hz, 2H), 6.89 (d, J = 8.2 Hz, 2H), 5.00 (s, 2H), 3.66 (dt, J 
= 5.5, 2.4 Hz, 1H), 0.73 (d, J = 3.2 Hz, 4H); 13C NMR (150 MHz, CDCl3) δ 153.6, 153.6, 137.7, 129.0, 
128.3, 127.9, 116.1, 116.1, 116.1, 100.0, 71.1, 51.5, 6.6. EA calc’d for C16H16O2: C, 79.97%; H, 6.71%, 





1-Cyclopropoxy-3-methoxybenzene (5g): The title compound was prepared from 3-methoxyphenol 
(37.2 mg, 0.3 mmol) according to General Procedure A. Purification by silica gel chromatography with 
10:1 hexanes:EtOAc as the eluent gave the product as a colorless oil (27.5 mg, 56% yield). 1H NMR 
(500 MHz, CDCl3) δ 7.18 (t, J = 8.2 Hz, 1H), 6.67 (ddd, J = 8.1, 2.3, 0.8 Hz, 1H), 6.62 (t, J = 2.4 Hz, 
1H), 6.53 (ddd, J = 8.2, 2.4, 0.8 Hz, 1H), 3.79 (d, J = 0.5 Hz, 3H), 3.75–3.69 (m, 1H), 0.77 (d, J = 4.5 
Hz, 4H); 13C NMR (150 MHz, CDCl3) δ 130.2, 107.8, 106.8, 101.8, 55.7, 51.2, 6.6; GC/MS (EI) m/z 
calcd for C10H12O2 [M]+ 164.0837, found 164. 
 
1-Cyclopropoxy-4-fluorobenzene (5h): The title compound was prepared from 4-fluorophenol (33.6 
mg, 0.3 mmol) according to General Procedure A. Purification by silica gel chromatography with 10:1 
hexanes:EtOAc as the eluent gave the product as a yellow oil (22.6 mg, 50% yield). 1H NMR (500 
MHz, CDCl3) δ 7.08–6.87 (m, 4H), 3.80–3.56 (m, 1H), 0.84–0.67 (m, 4H); 13C NMR (150 MHz, 
CDCl3) δ 116.2, 116.1, 116.0, 51.6, 30.1, 6.6. 
 
1-Chloro-4-cyclopropoxybenzene (5i): The title compound was prepared from 4-chlorophenol (38.4 
mg, 0.3 mmol) according to General Procedure A. Purification by silica gel chromatography with 10:1 
hexanes:EtOAc as the eluent gave the product as an orange oil (26.7 mg, 53% yield). 1H NMR (500 
MHz, CDCl3) δ 7.32 (dd, J = 10.7, 5.9 Hz, 2H), 7.06 (t, J = 8.3 Hz, 2H), 3.79 (tt, J = 5.9, 2.9 Hz, 1H), 
0.85 (d, J = 5.3 Hz, 4H); 13C NMR (150 MHz, CDCl3) δ 129.6, 127.3, 126.2, 116.6, 51.5, 6.6. 
 
1-Bromo-4-cyclopropoxybenzene (5j): The title compound was prepared from 4-bromophenol (51.9 
mg, 0.3 mmol) according to General Procedure A. Purification by silica gel chromatography with 10:1 
hexanes:EtOAc as the eluent gave the product as a yellow oil (34.5 mg, 54% yield). 1H NMR (500 
MHz, CDCl3) δ 7.37 (d, J = 7.1 Hz, 2H), 6.92 (d, J = 7.1 Hz, 2H), 3.70 (dd, J = 6.0, 3.4 Hz, 1H), 0.77 
(ddt, J = 5.4, 3.4, 1.9 Hz, 4H), 13C NMR (150 MHz, CDCl3) δ 132.6, 117.2, 113.6, 51.4, 30.1, 6.6; 
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GC/MS (EI) m/z calcd for C9H9OBr [M]+ 211.9837, found 212. 
 
1-Iodo-4-cyclopropoxybenzene (5k): The title compound was prepared from 4-iodophenol (66.0 mg, 
0.3 mmol) according to General Procedure A. Purification by silica gel chromatography with 10:1 
hexanes:EtOAc as the eluent gave the product as an orange solid (46.6 mg, 60% yield). mp = 49–50 ºC; 
1H NMR (500 MHz, CDCl3) δ 7.69–7.56 (d, 2H), 6.99–6.81 (d, 2H), 3.78 (m, J = 6.1, 2.8 Hz, 1H), 0.85 
(m, J = 7.5, 2.8 Hz, 4H); 13C NMR (150 MHz, CDCl3) δ 159.0, 138.3, 117.6, 83.2, 51.1, 6.3; GC/MS 
(EI) m/z calcd for C9H9OI [M]+ 259.9698, found 260. EA calc’d for C9H9OI: C, 41.56%; H, 3.49%, 
found: C, 41.37%; H, 3.14%. 
 
 
Methyl 4-cyclopropoxybenzoate (5l): The title compound was prepared from methyl 4-
hydroxybenzoate (45.6 mg, 0.3 mmol) according to General Procedure A. Purification by silica gel 
chromatography with 10:1 hexanes:EtOAc as the eluent gave the product as a yellow oil (19.6 mg, 34% 
yield). 1H NMR (500 MHz, CDCl3) δ 7.98 (d, J = 8.9 Hz, 2H), 7.06 (d, J = 8.8 Hz, 2H), 3.88 (s, 2H), 
3.78 (m, J = 6.1, 3.2 Hz, 1H), 0.97–0.65 (d, 4H); 13C NMR (150 MHz, CDCl3) δ 167.3, 163.2, 131.9, 
123.3, 115.1, 52.3, 51.6, 6.7. 
 
4-(Cyclopropyloxy)benzonitrile (5m): The title compound was prepared from 4-cyanophenol (35.6 
mg, 0.3 mmol) according to General Procedure B. The standard reaction conditions afforded an 
inseparable mixture of the desired O-cyclopropylated product, as well as O-allylated product S1. After 
aqueous workup, the mixture was redissolved in H2O (0.8 mL) and acetone (6.2 mL), and treated with 
OsO4 (2.5 wt% in i-PrOH, 0.15 mL, 0.015 mmol, 5 mol%) and NMO (53 mg, 0.45 mmol, 1.5 equiv). 
The reaction was stirred at rt, after which it was quenched with aqueous sodium bisulfite, extracted with 
EtOAc, dried over MgSO4, filtered, and concentrated in vacuo. Purification by silica flash column 
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chromatography (eluent: 2% EtOAc/Hex to 5% EtOAc/Hex) afforded the title compound as a colorless 
oil (13.0 mg, 27% yield). 1H NMR (500 MHz, CDCl3) δ 7.60–7.56 (m, 2H), 7.12–7.07 (m, 2H), 3.78 
(tt, J = 6.0, 3.0 Hz, 1H), 0.85–0.81 (m, 2H), 0.82–0.78 (m, 2H); 13C NMR (150 MHz, CDCl3) δ 162.6, 
134.0, 119.4, 116.0, 104.4, 51.5, 6.4. 
 
4-(Allyloxy)benzonitrile (S1):26 1H NMR (500 MHz, CDCl3) δ 7.63–7.55 (m, 2H), 6.99–6.94 (m, 2H), 
6.03 (ddd, J = 22.5, 10.6, 5.3 Hz, 1H), 5.48–5.38 (m, 1H), 5.36–5.28 (m, 1H), 4.59 (dt, J = 5.3, 1.6 Hz, 
2H). 
 
3-(Cyclopropyloxy)benzonitrile (5n): The title compound was prepared from 3-cyanophenol (35.6 mg, 
0.3 mmol) according to General Procedure B. The standard reaction conditions afforded an inseparable 
mixture of the desired O-cyclopropylated product, as well as O-allylated product S2. After aqueous 
workup, the mixture was redissolved in H2O (0.8 mL) and acetone (6.2 mL), and treated with OsO4 (2.5 
wt% in i-PrOH, 0.15 mL, 0.015 mmol, 5 mol%) and NMO (53 mg, 0.45 mmol, 1.5 equiv). The reaction 
was stirred at rt, after which it was quenched with aqueous sodium bisulfite, extracted with EtOAc, 
dried over MgSO4, filtered, and concentrated in vacuo. Purification by silica flash column 
chromatography (eluent: 2% EtOAc/Hex to 5% EtOAc/Hex) afforded the title compound as a colorless 
oil (14.1 mg, 30% yield). 1H NMR (500 MHz, CDCl3) δ 7.37 (t, J = 8.0 Hz, 1H), 7.34–7.32 (m, 1H), 
7.27–7.23 (m, 2H), 3.75 (tt, J = 6.0, 3.0 Hz, 1H), 0.85–0.81 (m, 2H), 0.81–0.78 (m, 2H); 13C NMR (150 
MHz, CDCl3) δ 159.3, 130.4, 124.9, 120.5, 118.9, 118.1, 113.2, 51.4, 6.4. 
 
2-(Allyloxy)benzonitrile (S2):27 1H NMR (500 MHz, CDCl3) 7.19–7.14 (m, 3H), 6.88 (d, J = 8.8 Hz, 
1H), 6.81 (d, J = 8.3 Hz, 2H), 5.99–6.06 (m, 1H), 5.42 (d, J = 17.7, 1H), 5.33 (d, J = 10.7 Hz, 1H), 4.56 




1-(Cyclopropyloxy)-3-nitrobenzene (5o): The title compound was prepared from 3-nitrophenol (41.7 
mg, 0.3 mmol) according to General Procedure B. The standard reaction conditions afforded an 
inseparable mixture of the desired O-cyclopropylated product, as well as O-allylated product S3. After 
aqueous workup, the mixture was redissolved in H2O (0.8 mL) and acetone (6.2 mL), and treated with 
OsO4 (2.5 wt% in i-PrOH, 0.15 mL, 0.015 mmol, 5 mol%) and NMO (53 mg, 0.45 mmol, 1.5 equiv). 
The reaction was stirred at rt, after which it was quenched with aqueous sodium bisulfite, extracted with 
EtOAc, dried over MgSO4, filtered, and concentrated in vacuo. Purification by silica flash column 
chromatography (eluent: 2% EtOAc/Hex to 10% EtOAc/Hex) afforded the title compound as a yellow 
oil (14.8 mg, 28% yield). 1H NMR (500 MHz, CDCl3) δ 7.92 (t, J = 2.3 Hz, 1H), 7.86–7.81 (m, 1H), 
7.42 (t, J = 8.2 Hz, 1H), 7.34–7.30 (m, 1H), 3.82 (tt, J = 6.2, 2.9 Hz, 1H), 0.89–0.84 (m, 2H), 0.84–0.79 
(m, 2H); 13C NMR (150 MHz, CDCl3) δ 160.0, 149.5, 130.2, 122.3, 116.4, 109.9, 51.9, 6.7. 
 
1-(Allyloxy)-3-nitrobenzene (S3):28 1H NMR (600 MHz, CDCl3) δ 7.25–7.80 (m, 4H), 6.11–5.99 (m, 
1H), 5.45 (dd, J = 17.2, 1.5 Hz, 1H), 5.37–5.32 (m, 1H), 4.63 (dt, J = 5.3, 1.5 Hz, 2H). 
 
tert-butyl-8-cyclopropoxy-3,4-dihydroisoquinoline-2(1H)-carboxylate (5p): The title compound was 
prepared from tert-butyl-8-hydroxy-3,4-dihydroisoquinoline-2(1H)-carboxylate (74.8 mg, 0.300 mmol) 
according to General Procedure C. Purification was performed using flash column chromatography (12g 
SiO2, Isco, 100% Hept. to 10% EtOAc) to afford the title compound as a colorless oil (27.0 mg, 31% 
yield). 1H NMR (600 MHz, CDCl3) δ 7.19–7.12 (m, 1 H) 7.08 (d, J = 8.07 Hz, 1 H) 6.77 (br d, J = 7.34 
Hz, 1 H) 4.45 (br s, 2 H) 3.80–3.72 (m, 1H) 3.64 (br t, J = 5.69 Hz, 2 H) 2.82 (br t, J = 5.50 Hz, 2 H) 
1.52 (s, 9 H) 0.78 (br d, J = 3.48 Hz, 4 H); 13C NMR (150 MHz, CDCl3) δ 155.48 (br s, 1C), 154.99 (br 
s, 1C), 135.85 (br s, 1C), 126.57, 122.49 (br s, 1C), 121.08 (br s, 1C), 109.62, 79.55, 50.76, 41.53 (br s, 
1C), 40.97–40.39 (m, 1C), 29.00 (br s, 1C), 28.49 (s, 3C), 6.20 (br s, 2C); HRMS (ESI-TOF) m/z calcd 




2-(4-cyclopropoxyphenyl)pyridine (5q): The title compound was prepared from 4-(pyridin-2-
yl)phenol (51.3 mg, 0.3 mmol) according to General Procedure A. Purification by silica gel 
chromatography with 10:1 hexanes:EtOAc as the eluent gave the product as an off-white solid (26.6 mg, 
42% yield). mp = 82–84 ºC; 1H NMR (500 MHz, CDCl3) δ 8.66 (d, J = 4.8 Hz, 1H), 7.97–7.93 (m, 
2H), 7.71 (dd, J = 23.5, 7.8 Hz, 2H), 7.22–7.11 (m, 3H), 3.80 (t, J = 4.6 Hz, 1H), 0.87–0.74 (m, 4H); 13C 
NMR (150 MHz, CDCl3) δ 160.1, 157.1, 149.3, 137.1, 132.1, 128.3, 121.6, 120.1, 115.4, 51.1, 6.4; 
HRMS (ESI-TOF) m/z calcd for C14H14NO [M+H]+ 212.1070, found 212.1064. 
 
2-(4-Cyclopropoxyphenyl)thiophene (5r): The title compound was prepared from 4-(thiophen-2-
yl)phenol (52 mg, 0.3 mmol) according to General Procedure A. Purification by silica gel 
chromatography with 10:1 hexanes:EtOAc as the eluent gave the product as an off-white solid (39.5 mg, 
61% yield). mp = 88–89 ºC; 1H NMR (500 MHz, CDCl3) δ 7.71–7.53 (m, 2H), 7.32–7.24 (m, 2H), 
7.27–7.03 (m, 3H), 3.94–3.76 (m, 1H), 0.88 (d, J = 5.1 Hz, 4H); 13C NMR (150 MHz, CDCl3) δ 159.0, 
144.8, 128.3, 128.0, 127.5, 124.3, 122.5, 115.8, 51.3, 6.7; GC/MS (EI) m/z calcd for C13H12OS [M]+ 
216.0609, found 216. EA calc’d for C13H12OS: C, 72.19%; H, 5.59%, found: C, 72.31%; H, 6.00%. 
 
 
1,3-Dicyclopropyl-1,3-dihydro-2H-benzimidazol-2-one (8a): The title compound was prepared from 
2-hydroxybenzimidazole (40.2 mg, 0.3 mmol) according to General Procedure B. Purification by silica 
flash column chromatography (eluent: 5% EtOAc/Hexane to 20% EtOAc/Hexane) afforded the title 
compound as a white solid (31.8 mg, 49% yield), along with separable mono-cyclopropylated product 
8a’. mp = 92–94 °C; 1H NMR (500 MHz, CDCl3) δ 7.21–7.13 (m, 2H), 7.12–7.04 (m, 2H), 2.83 (tt, J = 
7.0, 3.7 Hz, 2H), 1.11–1.05 (m, 4H), 0.99 (ddd, J = 8.0, 5.4, 3.8 Hz, 4H); 13C NMR (150 MHz, CDCl3) 
δ 155.0, 130.1, 121.2, 108.4, 22.5, 6.0; HRMS (ESI-TOF) m/z calcd for C13H15N2O [M+H]+ 215.1184, 
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found 215.1180.  
 
1-Cyclopropyl-1H-benzimidazol-2-ol (8a’): The title compound was prepared according to the 
procedure described above for 8a and was isolated as a white solid (7.7 mg, 15% yield). mp = 184–
188 °C; 1H NMR (CDCl3, 500 MHz) δ 10.03 (brs, 1H, OH), 7.23–7.19 (m, 1H), 7.14–7.04 (m, 3H), 
2.91 (tt, J = 7.0, 3.6 Hz, 1H), 1.18–1.09 (m, 2H), 1.08–1.02 (m, 2H); 13C NMR (CDCl3, 150 MHz) δ 
156.1, 131.5, 127.6, 121.7, 121.4, 109.5, 108.9, 22.4, 6.2; HRMS (ESI-TOF) m/z calcd for C10H11N2O 
[M+H]+ 175.0871, found 175.0876; X-ray (single-crystal): Colorless block crystals of X-ray diffraction 
quality were obtained by slow evaporation of a solution of 8a’ in CDCl3 (CCDC 1584673).29 
 
1-Cyclopropyl-3-methyl-1,3-dihydro-2H-benzimidazol-2-one (8b): The title compound was prepared 
from 1-methyl-1,3-dihydro-2H-benzimidazol-2-one (44.5 mg, 0.3 mmol) according to General 
Procedure B. Purification by silica flash column chromatography (eluent: 10% EtOAc/Hex) afforded the 
title compound as a white solid (43.0 mg, 76% yield). mp = 84–86 °C; 1H NMR (500 MHz, CDCl3) δ 
7.20–7.15 (m, 1H), 7.10–7.05 (m, 2H), 6.95–6.90 (m, 1H), 3.36 (s, 3H), 2.86 (tt, J = 7.1, 3.7 Hz, 1H), 
1.11–1.06 (m, 2H), 1.02–0.97 (m, 2H); 13C NMR (150 MHz, CDCl3) δ 154.8, 130.3, 129.8, 121.3, 
121.1, 108.5, 107.2, 27.0, 22.6, 6.1; HRMS (ESI-TOF) m/z calcd for C11H13N2O [M+H]+ 189.1028, 
found 189.1022. 
 
3-Cyclopropylbenzo[d]oxazol-2(3H)-one (8c):  The title compound was prepared from 
2-hydroxybenzoxazolinone (40.5 mg, 0.3 mmol) according to General Procedure B. Purification by 
silica flash column chromatography (eluent: 5 % EtOAc/Hex to 10% EtOAc/Hex) afforded the title 
compound as a white solid (45.3 mg, 86% yield). mp = 62–63 °C; 1H NMR (500 MHz, CDCl3) δ 7.21–
7.13 (m, 3H), 7.12–7.08 (m, 1H), 2.92 (tt, J = 7.0, 3.6 Hz, 1H), 1.15–1.08 (m, 2H), 1.08–1.02 (m, 2H); 
13C NMR (150 MHz, CDCl3) δ 154.4, 142.3, 132.0, 123.8, 122.5, 109.9, 109.2, 23.3, 6.0; HRMS (ESI-
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TOF) m/z calcd for C9H9N2O2 [M+H]+ 177.0659, found 177.0659. 
 
6-Chloro-3-cyclopropyl-1,3-benzoxazol-2(3H)-one (8d): The title compound was prepared from 
6-chlorobenzoxazol-2(3H)-one (50.9 mg, 0.3 mmol) according to General Procedure B. Purification by 
silica flash column chromatography (eluent: 10% EtOAc/Hex to 20% EtOAc/Hex) afforded the title 
compound as an orange solid (44.3 mg, 70% yield). mp 110–112 °C; 1H NMR (500 MHz, CDCl3) δ 
7.18–7.12 (m, 2H), 7.08–7.03 (m, 1H), 2.90 (tt, J = 7.0, 3.6 Hz, 1H), 1.15–1.07 (m, 2H), 1.05–0.98 (m, 
2H); 13C NMR (125 MHz, CDCl3) δ 154.0, 142.6, 130.8, 128.1, 123.9, 110.8, 109.7, 23.4, 6.0; GC/MS 
(EI) m/z calcd for C10H8ClNO2 [M]+ 209.0244, found 209. 
 
1-Cyclopropylquinolin-2(1H)-one (9a): The title compound was prepared from 2-hydroxyquinoline 
(43.5 mg, 0.3 mmol) according to General Procedure B. Purification by silica flash column 
chromatography (eluent: 30% EtOAc/Hex to 50% EtOAc/Hex) afforded the title compound as a yellow 
oil (41.0 mg, 74% yield). 1H NMR (500 MHz, CDCl3) δ 7.81 (d, J = 8.5 Hz, 1H), 7.59 (d, J = 9.5 Hz, 
1H), 7.55–7.45 (m, 2H), 7.18 (t, J = 7.5 Hz, 1H), 6.59 (d, J = 9.4 Hz, 1H), 2.93 (tt, J = 7.7, 4.1 Hz, 1H), 
1.39–1.30 (m, 2H), 0.93–0.85 (m, 2H); 13C NMR (125 MHz, CDCl3) δ 163.8, 141.1, 139.1, 130.0, 
128.6, 122.5, 122.2, 121.0, 115.6, 26.2, 10.5; HRMS (ESI-TOF) m/z calcd for C12H12NO [M+H]+ 
186.0913, found 186.0914. 
 
1-Cyclopropylpyridin-2-one (9b): The title compound was prepared from 2-hydroxypyridine (47.6 
mg, 0.5 mmol) according to General Procedure B. Purification by silica flash column chromatography 
(eluent: 2% MeOH/DCM to 5% MeOH/DCM), followed by preparative TLC (eluent: 5% MeOH/DCM) 
afforded the title compound as a yellow oil (24.8 mg, 37% yield). The connectivity (i.e., N- versus O-
cyclopropylation) was confirmed by NOESY analysis and by the diagnostic carbonyl signal at 164.3 
ppm in the 13C NMR spectrum. 1H NMR (500 MHz, CDCl3) δ 8.63–8.57 (m, 2H), 7.87–7.83 (m, 1H), 
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7.44 (tt, J = 6.8, 1.2 Hz, 1H), 4.64 (tt, J = 7.7, 3.6 Hz, 1H), 2.47–2.42 (m, 2H), 2.19–2.15 (m, 2H); 
13C NMR (125 MHz, CDCl3) δ 164.3, 139.0, 136.9, 120.9, 105.7, 32.3, 6.8; HRMS (ESI-TOF) m/z 
calcd for C8H10NO [M+H]+ 136.0757, found 136.0757. 
 
1-Cyclopropyl-4-methylpyridin-2-one (9c): The title compound was prepared from 2-hydroxy-4-
methylpyridine (32.7 mg, 0.3 mmol) according to General Procedure B. Purification by silica flash 
column chromatography (eluent: DCM to 2% MeOH/DCM) afforded the title compound as a pale-
yellow oil (31.9 mg, 71% yield). 1H NMR (500 MHz, CDCl3) δ 7.11 (d, J = 7.1 Hz, 1H), 6.29 (s, 1H), 
5.92 (dd, J = 7.1, 1.9 Hz, 1H), 3.24 (tt, J = 7.6, 4.2 Hz, 1H), 2.10 (s, 3H), 1.09–1.01 (m, 2H), 0.82–0.75 
(m, 2H); 13C NMR (125 MHz, CDCl3) δ 164.2, 150.6, 135.8, 119.2, 108.2, 31.8, 21.2, 6.7; HRMS 
(ESI-TOF) m/z calcd for C9H12NO [M+H]+ 150.0913, found 150.0912. 
 
1-Cyclopropyl-5-fluoropyridin-2-one (9d): The title compound was prepared from 2-hydroxy-5-
fluoropyridine (33.9 mg, 0.3 mmol) according to General Procedure B. Purification by silica flash 
column chromatography (eluent: DCM to 2% MeOH/DCM) afforded the title compound as a pale-
yellow oil (29.0 mg, 63% yield). 1H NMR (500 MHz, CDCl3) δ 7.25–7.19 (m, 1H), 7.17 (t, J = 3.9 Hz, 
1H), 6.48 (dd, J = 10.0, 5.4 Hz, 1H), 3.30 (tt, J = 7.7, 4.3 Hz, 1H), 1.14–1.09 (m, 2H), 0.86–0.81 (m, 
2H); 13C NMR (125 MHz, CDCl3) δ 162.3, 147.1 (d, J = 231 Hz), 131.0 (d, J = 24 Hz), 122.3 (d, J = 37 
Hz), 121.5 (d, J = 7 Hz), 32.7, 7.1; 19F NMR (CDCl3, 376 MHz, CDCl3) δ −149.35; HRMS (ESI-TOF) 
m/z calcd for C8H9FNO [M+H]+ 154.0663, found 154.0663. 
 
1-Cyclopropyl-5-chloropyridin-2-one (9e): The title compound was prepared from 2-hydroxy-5-
chloropyridine (38.9 mg, 0.3 mmol) according to General Procedure B. Purification by silica flash 
column chromatography (eluent: DCM to 2% MeOH/DCM), followed by preparative TLC (eluent: 2% 
MeOH/DCM) afforded the title compound as a yellow oil (33.8 mg, 66% yield). 1H NMR (500 MHz, 
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CDCl3) δ 7.30 (d, J = 2.8 Hz, 1H), 7.21 (dd, J = 9.7, 2.9 Hz, 1H), 6.48 (d, J = 9.7 Hz, 1H), 3.28 (tt, J = 
7.6, 4.2 Hz, 1H), 1.15–1.09 (m, 2H), 0.86–0.82 (m, 2H); 13C NMR (151 MHz, CDCl3) δ 162.7, 140.1, 
134.7, 121.8, 112.0, 32.9, 31.1, 7.1; HRMS (ESI-TOF) m/z calcd for C8H9ClNO [M+H]+ 170.0367, 
found 170.0367. 
 
1-Cyclopropyl-6-methylpyridin-2(1H)-one (9f): The title compound was prepared from 
6-methylpyridin-2(1H)-one (32.7 mg, 0.300 mmol) according to General Procedure C. Purification was 
performed using flash column chromatography (12 g SiO2, Isco, 100% Hept. to 10% MeOH/EtOAc) to 
afford the title compound as a pale-yellow gum (27.5 mg, 61% yield). 1H NMR (400MHz, CDCl3) δ 
7.15 (dd, J = 9.2, 6.7 Hz, 1H), 6.39 (d, J = 9.2 Hz, 1H), 5.97 (d, J = 6.7 Hz, 1H), 2.83 (tt, J = 7.1, 4.2 
Hz, 1H), 2.46 (s, 3H), 1.31–1.23 (m, 2H), 0.92–0.85 (m, 2H); 13C NMR (100 MHz, CDCl3) δ 165.24, 
148.59, 138.60, 118.44, 106.83, 28.08, 20.53, 10.33 (s, 2C); HRMS (ESI-TOF) m/z calcd for C9H11NO+ 
[M+H]+ 150.0913, found 150.0915. 
 
tert-Butyl-7-cyclopropyl-8-oxo-3,4,7,8-tetrahydro-2,7-naphthyridine-2(1H)-carboxylate (9g): The 
title compound was prepared from tert-butyl-8-oxo-3,4,7,8-tetrahydro-2,7-naphthyridine-2(1H)-
carboxylate (75.1 mg, 0.300 mmol) according to General Procedure C. Purification was performed 
using flash column chromatography (12g SiO2, Isco, 100% Hept. to 10% MeOH/EtOAc) to afford the 
title compound as a pale-yellow gum (55.4 mg, 63% yield). 1H NMR (600 MHz, CDCl3) δ 7.12 (br d, 
J=6.97 Hz, 1 H) 5.95 (br d, J = 6.97 Hz, 1 H) 4.39 (s, 2 H) 3.61 (br t, J = 5.59 Hz, 2 H) 3.34 (dt, J = 
7.24, 3.53 Hz, 1 H) 2.64–2.56 (m, 2 H) 1.50 (d, J = 1.10 Hz, 9 H) 1.12 (br d, J = 7.15 Hz, 2 H) 0.83–
0.88 (m, 2 H); 13C NMR (150MHz, CDCl3) δ = 162.04, 154.95 (br s, 1C), 144.63 (br s, 1C), 133.18, 
123.98 (br s, 1C), 106.95 (br s, 1C), 79.95 (br s, 1C), 42.28 (br s, 1C), 39.47 (br s, 1C), 31.77, 28.52, 





N-Cyclopropyl-N-(pyridin-2-yl)acetamide (10a): The title compound was prepared from 
2-acetamidopyridine (40.8 mg, 0.3 mmol) according to General Procedure B. Purification by silica flash 
column chromatography (eluent: 1% MeOH/DCM) afforded the title compound as a brown oil (47.0 
mg, 89% yield). 1H NMR (500 MHz, CDCl3) δ 8.45 (d, J = 4.7 Hz, 1H), 7.68 (td, J = 7.7, 2.0 Hz, 1H), 
7.21–7.10 (m, 2H), 3.11 (tt, J = 7.2, 3.8 Hz, 1H), 2.16 (s, 3H), 0.95–0.84 (m, 2H), 0.60–0.46 (m, 2H); 
13C NMR (150 MHz, CDCl3) δ 172.8, 155.3, 148.8, 137.8, 122.2, 121.8, 30.5, 23.6, 9.2; HRMS (ESI-
TOF) m/z calcd for C10H13N2O [M+H]+ 177.1022, found 177.1021. 
 
N-Cyclopropylpyrazin-2-amine (10b): The title compound was prepared from 2-aminopyrimidine 
(28.5 mg, 0.3 mmol) according to General Procedure B. Purification by silica flash column 
chromatography (eluent: 1–2% MeOH/DCM) afforded the title compound as a pale-yellow solid (13.2 
mg, 33% yield). mp = 82–85 °C; 1H NMR (600 MHz, CDCl3) δ 8.34 (s, 2H), 6.58 (t, J = 4.8 Hz, 1H), 
5.67 (brs, 1H, –NH), 2.77 (dddd, J = 9.2, 7.1, 3.6, 2.1 Hz, 1H), 0.89–0.80 (m, 2H), 0.59–0.52 (m, 2H); 
13C NMR(150 MHz, CDCl3) δ 163.4, 158.2, 111.2, 111.2, 23.9, 7.5, 7.5; HRMS (ESI-TOF) m/z calcd 
for C7H10N3 [M+H]+ 136.0869, found 136.0871. 
 
5-Hydroxy-N1,N1-dimethyl-N3-(5-methylpyridin-2-yl)isophthalamide (S4): The title compounds was 
prepared in a similar method as a previously published Pfizer patent (white solid).30 mp = 202–205 °C; 
1H NMR (400 MHz, DMSO-d6) δ 10.64 (s, 1H), 9.97 (s, 1H), 8.21 (s, 1H), 8.04 (d, J = 8.4 Hz, 1H), 
7.65 (dd, J = 2.0, 8.5 Hz, 1H), 7.47 (s, 1H), 7.43–7.36 (m, 1H), 6.93 (dd, J = 1.3, 2.1 Hz, 1H), 2.98 (br s, 
3H), 2.93 (br s, 3H), 2.28 (s, 3H); 13C NMR (100 MHz, DMSO-d6) δ 169.9, 165.6, 157.8, 150.4, 148.2, 
138.9, 138.4, 136.1, 129.3, 117.5, 117.2, 116.2, 114.9, 35.2, 17.8 (carbon signal suspected under solvent 





N1-Cyclopropyl-5-hydroxy-N3,N3-dimethyl-N1-(5-methylpyridin-2-yl)isophthalamide (10c): The 
title compound was prepared from 5-hydroxy-N1,N1-dimethyl-N3-(5-methylpyridin-2-yl)isophthalamide 
(S4) (180 mg, 0.6 mmol) according to General Procedure C. Purification by ISCO (0–100% 
EtOAc/Heptanes, then 10% MeOH/EtOAc) afforded the title compound as a light tan foam (130 mg, 
64%).  Structure elucidated by HMBC. 1H NMR (400 MHz, DMSO-d6) δ 9.80 (s, 1 H), 8.26–8.08 (m, 1 
H), 7.57 (ddd, J = 8.07, 2.45, 0.61 Hz, 1 H), 7.16 (d, J = 8.07 Hz, 1 H), 6.81 (dd, J = 2.32, 1.47 Hz, 1 
H), 6.65 (dd, J = 2.38, 1.41 Hz, 1 H), 6.60 (t, J = 1.41 Hz, 1 H), 3.10 (tt, J = 7.21, 3.73 Hz, 1 H), 2.90 
(br s, 3 H), 2.62 (br s, 3 H), 2.23 (s, 3 H), 0.81–0.69 (m, 2 H), 0.63–0.52 (m, 2 H); 13C NMR (100 MHz, 
DMSO-d6) δ 171.1, 169.6, 157.3, 153.5, 149.1, 139.0, 138.9, 137.7, 132.0, 122.5, 116.9, 115.9, 115.30, 
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